1.72
price down icon4.97%   -0.09
after-market After Hours: 1.74 0.02 +1.16%
loading
Macrogenics Inc stock is traded at $1.72, with a volume of 524.86K. It is down -4.97% in the last 24 hours and up +0.58% over the past month. Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
See More
Previous Close:
$1.81
Open:
$1.8
24h Volume:
524.86K
Relative Volume:
0.43
Market Cap:
$108.71M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.0886
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
+15.44%
1M Performance:
+0.58%
6M Performance:
-28.33%
1Y Performance:
-49.85%
1-Day Range:
Value
$1.72
$1.85
1-Week Range:
Value
$1.44
$1.87
52-Week Range:
Value
$0.9897
$5.10

Macrogenics Inc Stock (MGNX) Company Profile

Name
Name
Macrogenics Inc
Name
Phone
301-251-5172
Name
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Name
Employee
341
Name
Twitter
@macrogenics
Name
Next Earnings Date
2025-03-07
Name
Latest SEC Filings
Name
MGNX's Discussions on Twitter

Compare MGNX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MGNX
Macrogenics Inc
1.72 114.40M 139.77M -97.62M -61.71M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
389.08 99.27B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
586.96 62.28B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.18 59.14B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
707.96 43.34B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
300.14 36.72B 3.81B -644.79M -669.77M -6.24

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-07-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-01-24 Downgrade BTIG Research Buy → Neutral
Jul-31-24 Downgrade B. Riley Securities Buy → Neutral
Jul-31-24 Downgrade Guggenheim Buy → Neutral
May-10-24 Downgrade BMO Capital Markets Outperform → Market Perform
May-10-24 Downgrade Stifel Buy → Hold
May-10-24 Downgrade TD Cowen Buy → Hold
Apr-26-24 Initiated B. Riley Securities Buy
Apr-09-24 Upgrade TD Cowen Hold → Buy
Mar-04-24 Reiterated BTIG Research Buy
Feb-14-24 Downgrade H.C. Wainwright Buy → Neutral
Dec-20-23 Upgrade Citigroup Neutral → Buy
Nov-07-23 Upgrade Guggenheim Neutral → Buy
Mar-17-23 Downgrade Guggenheim Buy → Neutral
Nov-22-22 Downgrade Cowen Outperform → Market Perform
Nov-14-22 Upgrade BMO Capital Markets Market Perform → Outperform
Jul-18-22 Downgrade SMBC Nikko Outperform → Neutral
Jul-11-22 Downgrade BMO Capital Markets Outperform → Market Perform
May-04-22 Downgrade Guggenheim Buy → Neutral
Feb-28-22 Upgrade Citigroup Neutral → Buy
Feb-11-22 Initiated BMO Capital Markets Outperform
Feb-04-22 Initiated SMBC Nikko Outperform
Nov-17-21 Resumed Guggenheim Buy
Oct-19-21 Initiated JMP Securities Mkt Outperform
Oct-15-21 Resumed BTIG Research Buy
Apr-26-21 Resumed Credit Suisse Outperform
Mar-12-21 Upgrade Barclays Underweight → Overweight
Dec-22-20 Resumed H.C. Wainwright Buy
Aug-03-20 Downgrade Citigroup Buy → Neutral
Jun-01-20 Upgrade Guggenheim Neutral → Buy
May-26-20 Reiterated H.C. Wainwright Buy
Mar-04-20 Initiated Barclays Underweight
Dec-19-19 Initiated Cantor Fitzgerald Overweight
Dec-18-19 Initiated Cantor Fitzgerald Overweight
Nov-21-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Nov-20-19 Resumed Guggenheim Neutral
May-03-19 Upgrade Wedbush Neutral → Outperform
Apr-12-19 Initiated Guggenheim Neutral
Feb-07-19 Upgrade Citigroup Sell → Buy
Feb-07-19 Downgrade Wedbush Outperform → Neutral
Feb-06-19 Upgrade Raymond James Underperform → Mkt Perform
Feb-04-19 Downgrade Citigroup Neutral → Sell
Dec-10-18 Downgrade Raymond James Outperform → Underperform
Sep-10-18 Resumed BTIG Research Buy
May-31-18 Initiated Evercore ISI Outperform
Mar-05-18 Initiated H.C. Wainwright Buy
Mar-31-17 Initiated Raymond James Outperform
View All

Macrogenics Inc Stock (MGNX) Latest News

pulisher
05:50 AM

MacroGenics' new CEO Risser aims to cut costs, boost revenue through strategic partnerships - The Business Journals

05:50 AM
pulisher
02:27 AM

Does MacroGenics Inc. qualify in momentum factor screeningJuly 2025 Patterns & Fast Gain Stock Trading Tips - Newser

02:27 AM
pulisher
01:18 AM

Macrogenics plunged 1.27% in after-hours trading as Timothy Anderson, a large-cap analyst, spoke at BofA Securities 2025, discussing Johnson & Johnson's strategies - AInvest

01:18 AM
pulisher
10:20 AM

Is MacroGenics Inc. building a consolidation baseJuly 2025 Decliners & High Conviction Buy Zone Picks - Newser

10:20 AM
pulisher
09:28 AM

Trend analysis for MacroGenics Inc. this weekMarket Volume Report & Daily Entry Point Trade Alerts - Newser

09:28 AM
pulisher
06:37 AM

How to build a custom watchlist for MacroGenics Inc.July 2025 Movers & Reliable Entry Point Alerts - Newser

06:37 AM
pulisher
02:07 AM

What to expect from MacroGenics Inc. in the next 30 days2025 Technical Patterns & Free Community Consensus Stock Picks - Newser

02:07 AM
pulisher
Aug 26, 2025

Is it too late to sell MacroGenics Inc.Dollar Strength & AI Enhanced Execution Alerts - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Is MacroGenics Inc. stock entering bullish territoryProfit Target & Technical Pattern Based Signals - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Chart based exit strategy for MacroGenics Inc.Jobs Report & Technical Pattern Based Buy Signals - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Tools to monitor MacroGenics Inc. recovery probabilityEarnings Trend Report & Verified Entry Point Signals - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Short Covering May Lift MacroGenics Inc. in Near Term getLinesFromResByArray error: size == 0 - 더경남뉴스

Aug 26, 2025
pulisher
Aug 26, 2025

Combining price and volume data for MacroGenics Inc.Take Profit & Weekly Breakout Stock Alerts - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Is MacroGenics Inc. forming a bottoming baseTrade Volume Summary & Daily Stock Trend Watchlist - Newser

Aug 26, 2025
pulisher
Aug 25, 2025

Is it time to cut losses on MacroGenics Inc.Market Performance Report & Weekly Hot Stock Watchlists - Newser

Aug 25, 2025
pulisher
Aug 24, 2025

Is now a turning point for MacroGenics Inc.Weekly Gains Report & Capital Efficient Trade Techniques - Newser

Aug 24, 2025
pulisher
Aug 24, 2025

What candlestick patterns are forming on MacroGenics Inc.Forecast Cut & High Accuracy Trade Alerts - Newser

Aug 24, 2025
pulisher
Aug 24, 2025

Published on: 2025-08-24 14:28:03 - Newser

Aug 24, 2025
pulisher
Aug 23, 2025

William Heiden Bought 909% More Shares In MacroGenics - ca.finance.yahoo.com

Aug 23, 2025
pulisher
Aug 23, 2025

Published on: 2025-08-23 06:00:37 - Newser

Aug 23, 2025
pulisher
Aug 22, 2025

Institutional Tools Highlight Unusual Flow in MacroGenics Inc.Quarterly Portfolio Summary & AI Driven Stock Price Forecasts - 더경남뉴스

Aug 22, 2025
pulisher
Aug 22, 2025

Risk Check: How liquid is MacroGenics Inc. stock2025 Major Catalysts & Weekly High Return Stock Opportunities - baoquankhu1.vn

Aug 22, 2025
pulisher
Aug 22, 2025

Insider Sell: Is MacroGenics Inc. stock a hidden gemSell Signal & Daily Profit Maximizing Trade Tips - theviewers.co.kr

Aug 22, 2025
pulisher
Aug 22, 2025

Director Makes Bold Move with Major MacroGenics Stock Purchase! - TipRanks

Aug 22, 2025
pulisher
Aug 22, 2025

Sentiment Turns Positive on MacroGenics Inc. — Reversal Ahead2025 Big Picture & Daily Growth Stock Tips - beatles.ru

Aug 22, 2025
pulisher
Aug 21, 2025

Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical Trials, Companies, Therapies, Pipeline | Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen - Barchart.com

Aug 21, 2025
pulisher
Aug 21, 2025

Macrogenics, Inc. shares rise 7.64% after-hours following Johnson & Johnson's $2bn US investment. - AInvest

Aug 21, 2025
pulisher
Aug 21, 2025

Is MacroGenics Inc. the Top Chart Pick This Week2025 Stock Rankings & AI Powered Trade Plan Recommendations - newsyoung.net

Aug 21, 2025
pulisher
Aug 21, 2025

What is MacroGenics Inc.’s market position2025 Price Action Summary & Free AI Powered Buy and Sell Recommendations - theviewers.co.kr

Aug 21, 2025
pulisher
Aug 20, 2025

Technical Models Detect Momentum Build in MacroGenics Inc.July 2025 Reactions & Stock Portfolio Risk Control - classian.co.kr

Aug 20, 2025
pulisher
Aug 19, 2025

Elliott Wave Theory Predicts Pullback in MacroGenics Inc.July 2025 Outlook & Consistent Growth Equity Picks - 클래시안

Aug 19, 2025
pulisher
Aug 19, 2025

MacroGenics Inc. Breakout Confirmed by Volume MetricsPortfolio Return Report & AI Driven Stock Movement Reports - 더경남뉴스

Aug 19, 2025
pulisher
Aug 19, 2025

DC InnoMacroGenics strikes potential $1.7B deal with Gilead | Quantum Computing is expanding - The Business Journals

Aug 19, 2025
pulisher
Aug 19, 2025

Will MacroGenics Inc. see short term momentumJuly 2025 Selloffs & Trade Opportunity Analysis Reports - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Why MacroGenics Inc. stock attracts strong analyst attentionIPO Watch & Community Driven Trade Alerts - Newser

Aug 19, 2025
pulisher
Aug 18, 2025

Can MacroGenics Inc. grow without dilution2025 Growth vs Value & Verified Short-Term Trading Plans - thegnnews.com

Aug 18, 2025
pulisher
Aug 18, 2025

MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Aug 18, 2025
pulisher
Aug 17, 2025

What the charts say about MacroGenics Inc. todayWeekly Trade Analysis & Reliable Entry Point Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Is MacroGenics Inc. stock ready for a breakoutJuly 2025 EndofMonth & Fast Entry High Yield Stock Tips - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Is now a turning point for MacroGenics IncEarnings Growth Summary & Daily Entry Point Trade Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Leerink Partners Has Lowered Expectations for MacroGenics (NASDAQ:MGNX) Stock Price - Defense World

Aug 17, 2025
pulisher
Aug 16, 2025

MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

MacroGenics price target lowered to $5 from $8 at Leerink - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

Rockville’s MacroGenics Appoints New President/CEO For First Time in 24 Years - The MoCo Show -

Aug 16, 2025
pulisher
Aug 16, 2025

MacroGenics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

Aug 16, 2025
pulisher
Aug 16, 2025

How MacroGenics Inc. stock performs during market volatilityEarnings Beat & Community Supported Trade Ideas - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

Macrogenics, Inc. shares fall 1.27% after-hours following Johnson & Johnson's presentation at BofA Securities 2025. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

MacroGenics appoints Eric Risser as CEO as Scott Koenig exits - The Business Journals

Aug 15, 2025
pulisher
Aug 15, 2025

Macrogenics: Leerink Partners lowers PT to $5, maintains Outperform rating. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

MacroGenics' CEO Transition and Lorigerlimab Trial Uncertainty Warrant Hold Rating Amid Partnership Exploration - AInvest

Aug 15, 2025

Macrogenics Inc Stock (MGNX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Macrogenics Inc Stock (MGNX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
HEIDEN WILLIAM K
Director
Aug 20 '25
Buy
1.49
49,500
73,755
111,000
Koenig Scott
Director
Aug 13 '25
Option Exercise
0.00
52,829
0
830,244
Bonvini Ezio
Sr VP, Research & CSO
Feb 15 '25
Option Exercise
0.00
16,665
0
124,414
Karrels James
SVP, CFO and Secretary
Feb 15 '25
Option Exercise
0.00
14,998
0
192,591
Koenig Scott
President and CEO
Feb 15 '25
Option Exercise
0.00
42,329
0
777,415
Peters Jeffrey Stuart
Senior VP and General Counsel
Feb 15 '25
Option Exercise
0.00
13,332
0
18,858
Risser Eric Blasius
Chief Operating Officer
Feb 15 '25
Option Exercise
0.00
16,665
0
62,422
Smith Beth Ann
VP, Controller & Treasurer
Feb 15 '25
Option Exercise
0.00
1,095
0
9,955
Smith Beth Ann
VP, Controller & Treasurer
Feb 15 '25
Sale
2.56
423
1,083
9,532
Spitznagel Thomas
Sr VP, Technical Ops
Feb 15 '25
Option Exercise
0.00
13,332
0
26,922
$24.78
price up icon 0.98%
$84.84
price up icon 1.00%
$24.80
price down icon 8.06%
$103.01
price down icon 1.70%
$134.53
price up icon 1.79%
biotechnology ONC
$300.14
price down icon 2.84%
Cap:     |  Volume (24h):